StageZero Life Sciences, Ltd. Announces Temporary Repricing of Warrants Expiring in 2023 and 2024
Toronto, Ontario--(Newsfile Corp. - June 20, 2023) - StageZero Life Sciences, Ltd. (TSX: SZLS) (OTCQB: SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that it has applied to the Toronto Stock Exchange (the "Exchange") for a temporary repricing of the exercise price of 8,730,647 outstanding common share purchase warrants (the "Warrants") expiring during 2023 and 2024.The...
2023-06-20 7:29 AM EDT
StageZero Life Sciences, Ltd Announces Results of Resolutions at Annual and Special Meeting
Toronto, Ontario--(Newsfile Corp. - June 7, 2023) - StageZero Life Sciences, Ltd (TSX: SZLS) (OTCQB: SZLSF) ("StageZero" or the "Company") is pleased to report that shareholders voted in favour of all of the tabled resolutions listed in the Company's management information circular dated April 28 2023 (the "Circular"), at its annual and special meeting of shareholders held on June 07, 2023(the "Meeting").The results of the vote for the election of directors are as follows:
2023-06-07 7:28 PM EDT
StageZero Life Sciences, Ltd. Special and Annual General Meeting Conference Call
Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - StageZero Life Sciences, Ltd. (TSX: SZLS) ("StageZero" or the "Company") today announced that it will host a conference call as part of its Special and Annual General Meeting of Shareholders on Wednesday June 7, 2023, so that all shareholders may follow along with the proceedings of the meeting.Annual General and Special Meeting Conference CallEvent Date: Wednesday June 7, 2023Time: 2:00pm ETWebcast Link: https://www.gowebcasting.com/12586Conference Call NumbersCanada/USA TF: 1-800-319-4610Toronto Toll: +1-416-915-3239International Toll: +1-604-638-5340Abo
2023-06-05 5:17 PM EDT
StageZero Life Sciences, Ltd Announces Q1 2023 Financial Results - 15.2% Growth in Revenue over Q4 2022 - and Operational Update
Toronto, Ontario--(Newsfile Corp. - May 16, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company"), a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced its first quarter financial results for the three months ended March 31, 2023, and provided an update on its business operations.For the quarter ended March 31, 2023, the Company generated revenue of $0.779 million....
2023-05-16 7:00 AM EDT
StageZero to Issue Q1 2023 Financial Results After Market Closes May 15, 2023
Toronto, Ontario--(Newsfile Corp. - May 15, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company") today announced that it will release its first quarter 2023 operational results after the market closes on Monday May 15, 2023. StageZero's Chairman and CEO, James Howard-Tripp, will host an investor webcast and conference call at 8:30am ET on Tuesday May 16, 2023, reviewing the operational results and discussing business developments.Analyst and Investor CallEvent Date: Tuesday May 16, 2023Time: 8:30 am ETWebcast Link:...
2023-05-15 10:51 AM EDT
StageZero Life Sciences, Ltd Announces Q4 2022 and Year End Financial Results and Operational Update
Toronto, Ontario--(Newsfile Corp. - March 31, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company"), a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced its fourth quarter and full year financial results for the three and twelve-months ended December 31, 2022, and provided an update on its business operations.For the year ended December 31, 2022 the Company generated revenue of...
2023-03-31 9:22 PM EDT
StageZero to Issue Q4 2022 Financial Results on Friday March 31
Toronto, Ontario--(Newsfile Corp. - March 30, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company") today announced that it will release its fourth quarter and year end 2022 operational results after the market closes on Friday March 31, 2023. StageZero's Chairman and CEO, James Howard-Tripp, will release a webcast presentation at 7:00am ET on Monday April 3, 2023, reviewing the operational results and discussing business developments.Analyst and Investor CallEvent Date: Monday April 3, 2023Time: 7:00 am ETWebcast Link:...
2023-03-30 3:06 PM EDT
StageZero to Issue Q4 2022 Financial Results and Hold Conference Call on Thursday March 30
Toronto, Ontario--(Newsfile Corp. - March 29, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company") today announced that it will release its fourth quarter and year end 2022 operational results after the market closes on Thursday March 30, 2023. StageZero's Chairman and CEO, James Howard-Tripp, will host a conference call and accompanying webcast at 6:00 p.m. ET on Thursday March 30, 2023, to review the operational results and discuss business developments.Analyst and Investor CallEvent Date: Thursday March 30,...
2023-03-29 7:10 PM EDT
Results from METRICs Study Informs Expansion of StageZero's New Care Oncology Protocol
Toronto, Ontario--(Newsfile Corp. - February 15, 2023) - StageZero Life Sciences, Ltd. (TSX: SZLS) (OTCQB: SZLSF) ("StageZero" or the "Company"), a global healthcare company providing solutions to help improve patient outcomes through early cancer detection and adjunctive metabolic cancer therapies, today announced significant enhancements to the company's proprietary Care Oncology Protocol ("COC Protocol"). Metabolically targeted drugs show promise as adjunctive therapy to make cancer cells more sensitive to chemotherapy, radiation and other standard of care treatments. By coupling the COC...
2023-02-15 12:56 PM EST
StageZero Life Sciences Announces Change of Date of Special Meeting of Shareholders; Will Combine with AGM in Q2 2023
Toronto, Ontario--(Newsfile Corp. - February 2, 2023) - StageZero Life Sciences, Ltd. (TSX: SZLS) (OTCQB: SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announced today that its special meeting (the "Meeting") originally scheduled for Tuesday February 28, will now be combined with the Annual General Meeting ("AGM") in Q2 2023. At the proposed Meeting, shareholders were...
2023-02-02 3:07 PM EST
StageZero Life Sciences Announces Extension of Warrants
Toronto, Ontario--(Newsfile Corp. - August 5, 2021) - StageZero Life Sciences, Ltd. (TSX: SZLS) ("StageZero" or the "Company") announces that it is extending the expiry date ("Warrant Extension") of 202,343 common share purchase warrants (the "Warrants") issued to a broker in connection with the Company's convertible debenture financing closed February 19, 2020.The Company and holder of the Warrants have agreed to the Warrant Extension whereby the current expiry of the Warrants being August 19, 2021, will be extended by six...
2021-08-05 6:53 PM EDT